Expertise in
5
conditions

Christoph Haefelin-Neumann

Hugstetter Str. 55, 
Freiburg, BW, DE 
Expertise in
5
conditions
Hugstetter Str. 55, 
Freiburg, BW, DE 

Overview

Christoph Haefelin-Neumann practices practicing medicine in Freiburg, Germany.

Mr. Haefelin-Neumann is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis D, Hepatitis C, Hepatitis B, and Liver Transplant.

He is actively involved in clinical research, co-authoring 134 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Hugstetter Str. 55, Freiburg, BW 79106, Germany
Other Locations
Hermann Herder Str, 11 79104, Freiburg, BW 79104, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3

134 Total Publications

Early C-reactive protein kinetics predict outcomes in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors: a multicenter, observational study comparing different C-reactive protein kinetic definitions.
Early C-reactive protein kinetics predict outcomes in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors: a multicenter, observational study comparing different C-reactive protein kinetic definitions.
Journal: Frontiers in oncology
Published: June 02, 2026

Frequently Asked Questions about Christoph Haefelin-Neumann

Is Christoph Haefelin-Neumann a top-rated expert for Hepatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Christoph Haefelin-Neumann is classified as an Distinguished expert for Hepatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Christoph Haefelin-Neumann participate in research or clinical trials?

Yes. Christoph Haefelin-Neumann has published 134 articles and abstracts on conditions like Hepatitis. You can view a list of Christoph Haefelin-Neumann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Haefelin-Neumann's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile